Biotech: Page
-
Getty Images
Year in PreviewWill 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A?
A series of uncertainties that kept dealmaking to a minimum last year could be reversing as pharma reloads pipelines ahead of the patent cliff explosion.
By Michael Gibney • Jan. 14, 2025 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: Industry shifts in R&D, policy and clinical trials
Coming changes that could impact pharma from drug development to launch.
By Meagan Parrish • Jan. 10, 2025 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Permission granted by Candel Therapeutics
Q&A // Biotech SpotlightAfter layoffs, a viral immunotherapy biotech bounced back with a late-stage prostate cancer win
Candel Therapeutics’ CEO had to prioritize a phase 3 program amid layoffs and cuts, and an end-of-year clinical success was the redemption he was looking for.
By Michael Gibney • Jan. 9, 2025 -
Scott Olson via Getty Images
3 trial readouts that could shake up the obesity market this year
A wave of new weight loss treatments is on the way, and drugmakers are scrambling for a foot in the door.
By Amy Baxter • Jan. 8, 2025 -
Getty Images
Opinion // Year in PreviewPharmaVoice’s Crystal Ball: The industry’s AI future
How AI will further transform the business of drug discovery and development in 2025.
By Meagan Parrish • Jan. 7, 2025 -
Getty Images
4 closely watched FDA approval dates in 2025 from J&J, Novo and more
A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in the new year.
By Alexandra Pecci • Jan. 6, 2025 -
Getty Images
4 companies to watch in the accelerating gene editing race
A handful of innovative startups are scrambling to gain a foothold as technology improves at a rapid clip.
By Kelly Bilodeau • Jan. 2, 2025 -
Getty Images
10 of our most read articles of 2024
The high drama of an election year, industry layoffs, patent cliff strategies and other key trends that shaped pharma in 2024.
By Meagan Parrish • Dec. 20, 2024 -
Getty Images
A biotech’s race to tackle the most severe hepatitis
Bluejay Therapeutics is one of just a handful of companies developing treatments for hepatitis D.
By Alexandra Pecci • Dec. 17, 2024 -
Courtesy of Roche
3 closely watched drugs that failed in the clinic
How recent setbacks and scattered successes could impact various sectors of the industry.
By Kelly Bilodeau • Dec. 16, 2024 -
Permission granted by Regeneron
Q&ARegeneron’s R&D approach scores dual wins against Alexion’s Ultomiris and in lymphoma
At this year’s ASH conference, Regeneron posted results for treatments that could disrupt the standards of care in two blood-related diseases.
By Michael Gibney • Dec. 12, 2024 -
Getty Images
Deep DiveEndometriosis drug research, long underfunded, confronts familiar problems in women’s health
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
By Delilah Alvarado • Dec. 11, 2024 -
Justin Sullivan via Getty Images
What’s next for 23andMe?
Amid its plummeting stock value, layoffs and cuts to its drug R&D program, the battered company is carrying on.
By Alexandra Pecci • Dec. 10, 2024 -
Getty Images
Psychedelics haven’t fulfilled clinical expectations, but new trial strategies could turn the tide
Leading companies in the psychedelics space have had trouble crossing the regulatory threshold. Here’s where they’re going wrong — and how to fix it.
By Kelly Bilodeau • Dec. 9, 2024 -
Courtesy of GSK
GSK taps a startup for shot at Alzheimer’s drug
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By Jacob Bell • Dec. 5, 2024 -
Getty Images
The big rebrand: Why these 4 biopharmas changed their name this year
Four companies that refreshed their mission and public persona with a new look.
By Alexandra Pecci • Dec. 4, 2024 -
Permission granted by Alexion/AstraZeneca
How Alexion markets a rare disease drug by ‘starting with the end in mind’
The biopharma, now an arm of AstraZeneca, needs to build the plane while flying it to be first in rare diseases with no other option.
By Michael Gibney • Dec. 3, 2024 -
Getty Images
Can the girl power of Arrivo’s depression drug help reverse its fortunes?
After failing a mid-stage trial, the biotech shifted course and is now targeting females with the goal of proving gender can play a role in depression outcomes.
By Kelly Bilodeau • Dec. 3, 2024 -
Getty Images
Milk-based therapies could be coming. This biotech CEO is aiming to lead the way.
Intrinsic Medicine is entering phase 2 trials in Parkinson’s disease and IBS for its human milk oligosaccharide drug candidates next year.
By Amy Baxter • Dec. 2, 2024 -
Getty Images
Q&A // Biotech SpotlightAn RNA biotech draws the blueprint for a late-stage Dravet syndrome trial and beyond
Stoke Therapeutics is entering phase 3 with its RNA medicine designed to treat a rare epileptic condition.
By Michael Gibney • Nov. 26, 2024 -
Chip Somodevilla via Getty Images
What might a Trump administration mean for the Biosecure Act?
It’s still likely U.S. biotechs and pharmas will have to cut ties with key Chinese partners — it’s just a matter of when.
By Amy Baxter • Nov. 20, 2024 -
Brad Penner/Imagn Images/Reuters
The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré syndrome and other autoimmune diseases.
By Alexandra Pecci • Nov. 19, 2024 -
Erik S. Lesser via Getty Images
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
Merck’s acquisition of Modifi Biosciences bucks common M&A trends in pharma.
By Kelly Bilodeau • Nov. 18, 2024 -
Getty Images
The first MASH drug could open the door for others — including GLP-1s
With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.
By Amy Baxter • Nov. 18, 2024 -
Getty Images
Where are they now? 4 biotechs that soared then crashed during the pandemic
How Novavax and others have restructured and trudged forward after their COVID-era high.
By Meagan Parrish • Nov. 15, 2024
Previous
